Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports outline breast cancer study findings from University of Toronto
January 29th, 2009
" The purpose of the study was to investigate the associations between uptake of In-111-DTPA-trastuzumab, tumour HER2 density and response to trastuzumab (Herceptin) of human breast cancer (BC) xenografts in athymic mice. Materials and methods The tumour uptake of In-111-DTPA-trastuzumab in athymic mice bearing BC xenografts with increasing HER2 density (0 to 3+) was evaluated," scientists in Toronto, Canada report. "Specific uptake ratios were established in biodistribution (SUR) and imaging studies (ROI-SUR) using In-111-labeled mouse IgG (In-111-DTPA-mIgG). Further corrections were made for circulating radioactivity using tumour-to-blood ratios defined as a...
Source: Women's Health Weekly (2009-01-29)
|
